| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Dept of Respiratory Medicine, Hannover Medical School, Hannover, Germany
CORRESPONDENCE: M. M. Hoeper, Hannover Medical School, Dept of Respiratory Medicine, Carl-Neuberg-Str. 1, 30625 Hannover, Germany. Fax: 49 5115328536. E-mail: hoeper.marius{at}mh-hannover.de
Keywords: Endothelin receptor antagonists, hypertension, prostaglandins, pulmonary, sildenafil
Received: June 27, 2005
Accepted July 26, 2005
Combination therapy may improve outcome in patients with severe pulmonary arterial hypertension (PAH).
PAH patients were treated according to a goal-oriented therapeutic strategy. Patients who did not reach the treatment goals with monotherapy received combination treatment according to a predefined strategy, including bosentan, sildenafil and inhaled iloprost. Intravenous iloprost and lung transplantation were reserved for treatment failures. End points were overall survival, transplantation-free survival, and survival free from transplantation and intravenous prostanoid treatment.
Between January 2002 and December 2004, 123 consecutive patients with PAH were treated according to the novel approach. Survival at 1, 2 and 3 yrs was 93.0, 83.1 and 79.9%, respectively, which was significantly better than the survival of a historical control group, as well as the expected survival. Compared to the historical control group, the use of combination treatment also significantly improved the combined end point of death, lung transplantation and need for intravenous iloprost treatment.
In conclusion, a therapeutic approach utilising combinations of bosentan, sildenafil and inhaled iloprost in conjunction with a goal-oriented treatment strategy provides acceptable long-term results in patients with severe pulmonary arterial hypertension, and reduces the need for intravenous prostaglandin treatment and lung transplantation.
This article has been cited by other articles:
|
|
 |
|
  J. Le Pavec, R. Souza, P. Herve, D. Lebrec, L. Savale, C. Tcherakian, X. Jais, A. Yaici, M. Humbert, G. Simonneau, et al. Portopulmonary Hypertension: Survival and Prognostic Factors Am. J. Respir. Crit. Care Med., September 15, 2008; 178(6): 637 - 643. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Nickel, T. Kempf, H. Tapken, J. Tongers, F. Laenger, U. Lehmann, H. Golpon, K. Olsson, M. R. Wilkins, J. S. R. Gibbs, et al. Growth Differentiation Factor-15 in Idiopathic Pulmonary Arterial Hypertension Am. J. Respir. Crit. Care Med., September 1, 2008; 178(5): 534 - 541. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Suntharalingam, C. M. Treacy, N. J. Doughty, K. Goldsmith, E. Soon, M. R. Toshner, K. K. Sheares, R. Hughes, N. W. Morrell, and J. Pepke-Zaba Long-term Use of Sildenafil in Inoperable Chronic Thromboembolic Pulmonary Hypertension Chest, August 1, 2008; 134(2): 229 - 236. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A E Lammers, A A Hislop, Y Flynn, and S G Haworth The 6-minute walk test: normal values for children of 4-11 years of age Arch. Dis. Child., June 1, 2008; 93(6): 464 - 468. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Chin and L. J. Rubin Pulmonary arterial hypertension. J. Am. Coll. Cardiol., April 22, 2008; 51(16): 1527 - 1538. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 National Pulmonary Hypertension Centres of the UK Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland Heart, March 1, 2008; 94(Suppl_1): i1 - i41. [Full Text] [PDF]
|
|
|
|
 |
|
 National Pulmonary Hypertension Centres of the UK Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland Thorax, March 1, 2008; 63(Suppl_2): ii1 - ii41. [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Hoeper and A. T. Dinh-Xuan Pulmonary hypertension: basic concepts and practical management Eur. Respir. J., February 1, 2008; 31(2): 236 - 237. [Full Text] [PDF]
|
|
|
|
|
|
M. M. Hoeper, H. J. Seyfarth, G. Hoeffken, H. Wirtz, E. Spiekerkoetter, M. W. Pletz, T. Welte, and M. Halank Experience with inhaled iloprost and bosentan in portopulmonary hypertension Eur. Respir. J., December 1, 2007; 30(6): 1096 - 1102. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Hoeper and F. Laenger Challenging cases in PH Eur. Respir. Rev., August 1, 2007; 16(102): 19 - 23. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Torbicki Cardiac magnetic resonance in pulmonary arterial hypertension: a step in the right direction Eur. Heart J., May 5, 2007; (2007) ehm074v1. [Full Text] [PDF]
|
|
|
|
|
|
M. M. Hoeper, M. W. Pletz, H. Golpon, and T. Welte Prognostic value of blood gas analyses in patients with idiopathic pulmonary arterial hypertension Eur. Respir. J., May 1, 2007; 29(5): 944 - 950. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Hoeper Observational trials in pulmonary arterial hypertension: low scientific evidence but high clinical value Eur. Respir. J., March 1, 2007; 29(3): 432 - 434. [Full Text] [PDF]
|
|
|
|
|
|
S. C. Mathai, R. E. Girgis, M. R. Fisher, H. C. Champion, T. Housten-Harris, A. Zaiman, and P. M. Hassoun Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension Eur. Respir. J., March 1, 2007; 29(3): 469 - 475. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S C Apostolopoulou, A Manginas, D V Cokkinos, and S Rammos Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year study Heart, March 1, 2007; 93(3): 350 - 354. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Mereles, N. Ehlken, S. Kreuscher, S. Ghofrani, M. M. Hoeper, M. Halank, F. J. Meyer, G. Karger, J. Buss, J. Juenger, et al. Exercise and Respiratory Training Improve Exercise Capacity and Quality of Life in Patients With Severe Chronic Pulmonary Hypertension Circulation, October 3, 2006; 114(14): 1482 - 1489. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Gomberg-Maitland Learning to pair therapies and the expanding matrix for pulmonary arterial hypertension: is more better? Eur. Respir. J., October 1, 2006; 28(4): 683 - 686. [Full Text] [PDF]
|
|
|
|
|
|
M. M. Hoeper, H. Leuchte, M. Halank, H. Wilkens, F. J. Meyer, H. J. Seyfarth, R. Wensel, F. Ripken, H. Bremer, S. Kluge, et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension Eur. Respir. J., October 1, 2006; 28(4): 691 - 694. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Bresser, J. Pepke-Zaba, X. Jais, M. Humbert, and M. M. Hoeper Medical Therapies for Chronic Thromboembolic Pulmonary Hypertension: An Evolving Treatment Paradigm Proceedings of the ATS, September 1, 2006; 3(7): 594 - 600. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Reichenberger, R. Voswinckel, E. Steveling, B. Enke, A. Kreckel, H. Olschewski, F. Grimminger, W. Seeger, and H. A. Ghofrani Sildenafil treatment for portopulmonary hypertension Eur. Respir. J., September 1, 2006; 28(3): 563 - 567. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Hoeper, T. Welte, G. Izbicki, D. Rosengarten, E. Picard, W. G. Kuschner, N. Galie, L. J. Rubin, and G. Simonneau Sildenafil citrate therapy for pulmonary arterial hypertension. N. Engl. J. Med., March 9, 2006; 354(10): 1091 - 1093. [Full Text] [PDF]
|
|
|
|
|
|
V. V. McLaughlin 'Raising the bar' for the treatment of pulmonary arterial hypertension Eur. Heart J., March 1, 2006; 27(5): 510 - 511. [Full Text] [PDF]
|
|
|
|
|
|
M. M. Hoeper and L. J. Rubin Update in pulmonary hypertension 2005. Am. J. Respir. Crit. Care Med., March 1, 2006; 173(5): 499 - 505. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
